TABLE 1.
Characteristic | No. of patients | % Total study population |
---|---|---|
Sex (men/women) | 155/19 | 89/11 |
Mean age (range) | 37 (21–63)b | |
Mean total body weight (range) | 77.7 (42–140)c | |
Baseline CD4 count (cells per μl) | ||
<100 | 35 | 20 |
<300 and >100 | 59 | 34 |
<300 | 80 | 46 |
Baseline viral RNA (copies/ml) | ||
>100,000 | 68 | 39 |
>50,000 and <100,000 | 43 | 25 |
>50,000 | 63 | 36 |
Race | ||
Caucasian | 136 | 78 |
Black | 21 | 12 |
Asian | 3 | 2 |
Hispanic | 7 | 4 |
Latin American | 4 | 2 |
Native American | 3 | 2 |
Concomitant medications | ||
Azole (fluconazole) | 25 (23) | 15 (13) |
Macrolide | 18 | 10 |
Quinolone | 12 | 8 |
Rifabutin | 5 | 3 |
History of liver disease | 60 | 34 |
LFTs grade 2 or higher | 51 | 29 |
Plasma M8-to-nelfinavir ratioa | ||
Low ratio (<0.1) | 6 | 3 |
Intermediate ratio (>0.1 and <0.3) | 67 | 38 |
High ratio (>0.3) | 37 | 21 |
M8 concentrations were available for only 110 of 174 patients in this study.
In years.
In kilograms.